Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical, Inc. reports developments from a clinical-stage biopharmaceutical business focused on miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal™ technology. News commonly centers on financial results, business updates, manufacturing and clinical-development spending, and progress for semaglutide-based implant candidates such as NPM-139 for chronic weight management and NPM-133 for type 2 diabetes.
The company’s updates also cover Cortigent, its wholly owned subsidiary developing brain implant devices based on precision neurostimulation technology. Cortigent disclosures include the Orion® Visual Cortical Prosthesis System, a cortical stimulation system under development to provide visual perception for blind persons, as well as equity financings, registered direct offerings, private placements, shareholder matters and governance updates.
Vivani Medical (NASDAQ: VANI) has announced the record date of October 8, 2025 for the spin-off of its neuromodulation subsidiary, Cortigent. Cortigent will become an independent, publicly-traded company on Nasdaq under the ticker symbol CRGT.
Cortigent specializes in brain implant devices and has achieved significant milestones, including FDA approval for its Orion® artificial vision system for the profoundly blind and completion of a 6-year Early Feasibility Study. The company is also developing a Stroke Recovery System for improving arm and hand motion in stroke patients.
Post spin-off, Vivani will focus on developing miniature, ultra long-acting GLP-1 implants for weight loss and type 2 diabetes treatment. The transaction is expected to complete by late-2025, subject to regulatory approvals and other conditions.
Vivani Medical (Nasdaq: VANI) has announced plans to initiate clinical trials for NPM-139, their semaglutide implant for chronic weight management. The company plans to begin a Phase 1 study in the first half of 2026, pending regulatory clearance, followed by a Phase 2 study.
The NPM-139 implant, utilizing NanoPortal™ technology, aims to provide Wegovy®-level efficacy with just once or twice-yearly administration. The Phase 1 study will evaluate safety, tolerability, and pharmacokinetics in GLP-1 naïve obese or overweight subjects, with low-dose Wegovy as control. The subsequent Phase 2 study will be a randomized, placebo-controlled, dose-ranging investigation over 4-6 months.
Vivani Medical (NASDAQ: VANI), a clinical-stage biopharmaceutical company, announced that CEO Adam Mendelsohn will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, in New York.
The presentation will showcase Vivani's portfolio of miniature, ultra long-acting drug implants powered by their proprietary NanoPortal™ technology. The company's focus is on addressing medication adherence in chronic disease management, with particular emphasis on NPM-139, a novel semaglutide implant scheduled for clinical development in 2026, pending regulatory approval.
Vivani Medical (NASDAQ: VANI) announced significant developments including a $10M equity financing through a private placement of 7.9M shares at $1.26 per share. The company reported promising results for its semaglutide implant NPM-139, which demonstrated ~20% weight loss maintained over six months in preclinical studies. The financing extends their runway into H2 2026.
Key developments include positive results from the LIBERATE-1 Phase 1 clinical study of NPM-115, plans to initiate NPM-139 clinical trials in 2026, and the upcoming spin-off of Cortigent as an independent public company. Q2 2025 financial results showed a cash balance of $8.1M, with R&D expenses increasing 35% to $4.8M and a net loss of $7.1M.
Vivani Medical (NASDAQ:VANI) reported significant progress in its drug implant development programs. The company announced positive results from two key studies: the LIBERATE-1 Phase 1 clinical study of NPM-115 (exenatide implant) and preclinical data for NPM-139 (semaglutide implant).
The LIBERATE-1 study met its primary objectives, demonstrating safety and tolerability of the NanoPortal™ implant technology. More notably, the NPM-139 preclinical study showed approximately 20% weight loss maintained for over 6 months with a single implant administration, suggesting potential for annual dosing.
Based on these results, Vivani is prioritizing the development of NPM-139, with clinical trials expected to begin in 2026. The decision is supported by the strong commercial performance of semaglutide-based products, which generated over $29B in sales in 2024.
Vivani Medical (NASDAQ: VANI) announced its CEO Adam Mendelsohn's upcoming participation in the American Association of Pharmaceutical Scientists' virtual workshop "Beyond GLP1s: Where the Science will Take Business Next" on May 13-14, 2025. Dr. Mendelsohn will present on "Addressing Patient Adherence: Advances in Drug Delivery" on May 14 at 11:15 am ET, focusing on Vivani's miniature drug implants and their proprietary NanoPortal™ technology.
The company's lead program, NPM-115, is a six-month GLP-1 (exenatide) implant for weight management, with results from the LIBERATE-1™ human study expected this year. Dr. Mendelsohn will also participate in a panel discussion at 2:00 pm ET about key hurdles and trends in GLP-1 drug class development.